These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 31912897)
1. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition? Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897 [TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors. Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326 [TBL] [Abstract][Full Text] [Related]
3. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. Li Y; Liu CF; Rao GW Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505 [TBL] [Abstract][Full Text] [Related]
4. Update on PARP Inhibitors in Breast Cancer. Zimmer AS; Gillard M; Lipkowitz S; Lee JM Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491 [TBL] [Abstract][Full Text] [Related]
5. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287 [TBL] [Abstract][Full Text] [Related]
6. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials. Crafton SM; Bixel K; Hays JL Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003 [TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Wang L; Wang Q; Xu Y; Cui M; Han L Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293 [TBL] [Abstract][Full Text] [Related]
8. Veliparib: a new therapeutic option in ovarian cancer? Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636 [TBL] [Abstract][Full Text] [Related]
9. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Moore KN; Monk BJ Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873 [TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development? Lightfoot M; Montemorano L; Bixel K Curr Oncol Rep; 2020 Feb; 22(3):29. PubMed ID: 32067102 [TBL] [Abstract][Full Text] [Related]
11. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680 [TBL] [Abstract][Full Text] [Related]
12. PARP and PARG inhibitors in cancer treatment. Slade D Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455 [TBL] [Abstract][Full Text] [Related]
13. The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. Chelariu-Raicu A; Zibetti Dal Molin G; Coleman RL Int J Gynecol Cancer; 2020 Oct; 30(10):1608-1618. PubMed ID: 32928926 [TBL] [Abstract][Full Text] [Related]
14. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review. Buege M; Mahajan PB Rev Recent Clin Trials; 2015; 10(4):326-39. PubMed ID: 26374559 [TBL] [Abstract][Full Text] [Related]
17. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer. Sulai NH; Tan AR Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621 [TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Chelariu-Raicu A; Trillsch F; Burges A; Czogalla B; Hester A; Wuerstlein R; Harbeck N; Mahner S Int J Gynecol Cancer; 2023 May; 33(5):812-822. PubMed ID: 36707086 [TBL] [Abstract][Full Text] [Related]
19. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]